Overview

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
Phase:
PHASE2
Details
Lead Sponsor:
Qlaris Bio, Inc.